Patents
Innovative Patents Driving the Future of Transdermal Science.
GRANTED
PATENTS:
Skinvisible has numerous patents granted, including comprehensive trade secrets on Invisicare, the foundation of all of our products and products formulated with it. Additionally, Skinvisible has been granted product-specific patents in the US for acne formulations, sunscreens (achieved 8-hour photostability) and cationic ingredients (stabilization). Skinvisible continues to seek patent opportunities in various markets where a topical or transdermal treatment would be effective.
- United States Patent No.: US9149490
Acne treatment composition and methods for using - United States Patent No.: US8128913
Sunscreen composition with enhanced UV-A absorber stability and methods - United States Patent No.: US8735422B2
Cationic pharmaceutically active ingredient containing composition, and methods for manufacturing and using.
PENDING
patents:
Skinvisible made a major advancement in the battle against obesity. The Company filed a provisional patent application covering formulations that leverage the Company's proprietary delivery technology Invisicare® for the transdermal administration of obesity drugs, followed by an expansion of the initial patent to cover a greater array of glucose-controlling agents and conditions.
"Transdermal Delivery Composition for Delivery of CB-1 Receptor Antagonists and/or GLP-1 Receptor Agonists, and Method of Delivery"
This initial patent filing ushers in a new era of efficient and convenient transdermal obesity drug delivery solutions. The patent application focuses on Invisicare transdermal delivery technology designed to incorporate CB-1 receptor antagonists and/or GPL-1 receptor agonists, two classes of drugs known for their potential in obesity management, into a lotion that is applied topically to the skin using a metered applicator.
"Transdermal Delivery Composition for Delivery of at Least One Glucose Controlling Agent, and Method of Delivering at Least One Glucose Controlling Agent"
This second transdermal patent application encompasses a wider range of active ingredients and additional conditions beyond obesity that can benefit from glucose-controlling agents such as diabetes.
News & Press
Releases
Ovation Science and Skinvisible Strengthen Partnership in Obesity Market with New Cannabinoid Delivery Patents
Ovation Science and Skinvisible Pharmaceuticals have expanded their partnership to advance patent-pending Invisicare® cannabinoid delivery technology for obesity and metabolic health. The collaboration leverages THC-V research, new patent protection, and the growing US$150B obesity therapy market.
Read more 
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
Skinvisible Pharmaceuticals announces major progress in 2024-2025 through its licensee, Quoin Pharmaceuticals, in developing QRX003 for Netherton Syndrome using Invisicare technology. With FDA clearance, global clinical trials, and regulatory success, Skinvisible advances innovative topical and transdermal therapies.
Read more 
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
Skinvisible Pharmaceuticals publishes groundbreaking research on transdermal obesity drug delivery using Invisicare technology. The study shows 99.6% transdermal penetration of GLP-1 actives, offering a non-invasive alternative to injections. Skinvisible seeks partnerships to bring transdermal obesity therapies to market.
Read more 
Skinvisible Unveils Promising Data on Transdermal Obesity Formulations
Skinvisible Pharmaceuticals announces breakthrough data on transdermal obesity drug delivery using Invisicare technology. Studies show up to 69% drug penetration, offering a non-invasive alternative to injections. Skinvisible seeks partners to bring transdermal obesity therapies to market.
Read more 
Skinvisible Expands Obesity Patent Application for Transdermal Delivery
Skinvisible Pharmaceuticals expands its obesity patent application for transdermal drug delivery using Invisicare technology. The innovation enhances systemic absorption of GLP-1 agonists, CB-1 antagonists, and SGLT-2 inhibitors, offering a needle-free alternative. Skinvisible seeks partners to bring this breakthrough to market.
Read more 
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment
Skinvisible Pharmaceuticals files a provisional patent for transdermal obesity drug delivery using Invisicare technology. This needle-free, topical solution enhances drug absorption and patient compliance, revolutionizing obesity treatment. Skinvisible seeks partners to bring this innovation to market.
Read more